DECREASED EXPRESSION OF ADHESION MOLECULES IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) CELLS OF PATIENTS TREATED WITH IBRUTINIB

被引：0
|
作者：
Guarini, A. [1 ,2 ]
De Propris, M. S. [1 ]
Milani, M. L. [1 ]
Intoppa, S. [1 ]
Faraone, S. [1 ]
Peragine, N. [1 ]
Mariglia, P. [1 ]
Puzzolo, M. C. [1 ]
Mauro, F. R. [1 ]
Del Giudice, I. [1 ]
Foa, R. [1 ]
机构：
[1] Sapienza Univ, Dept Cellular Biotechnol & Hematol, Rome, Italy
[2] Sapienza Univ, Dept Mol Med, Hematol, Rome, Italy
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E989
引用
收藏
页码：406 / 406
页数：1
相关论文
共 50 条
  • [41] Phase Ib Study of Ianalumab (VAY736) and Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL) on Ibrutinib Therapy
    Rogers, Kerry A.
    Flinn, Ian W.
    McGarry, Carolyn
    Gou, Liangke Connie
    Hassounah, Nadia
    Woo, Janghee
    Byrd, John C.
    BLOOD, 2020, 136
  • [42] BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression
    Hampel, Paul J.
    Call, Timothy G.
    Achenbach, Sara J.
    Rabe, Kari G.
    Ding, Wei
    Muchtar, Eli
    Kenderian, Saad S.
    Wang, Yucai
    Koehler, Amber
    Fonder, Amie
    Leis, Jose F.
    Schwager, Susan M.
    Van Dyke, Daniel L.
    Braggio, Esteban
    Slager, Susan L.
    Kay, Neil E.
    Parikh, Sameer A.
    BLOOD, 2019, 134
  • [43] Pattern of Use of Anticoagulation and/or Antiplatelet Agents in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ibrutinib Therapy
    Jones, Jeffrey A.
    Hillmen, Peter
    Coutre, Steven
    Tam, Constantine
    Furman, Richard R.
    Barr, Paul M.
    Schuster, Stephen J.
    Kipps, Thomas J.
    Flinn, Ian W.
    Jaeger, Ulrich
    Burger, Jan A.
    Cheng, Mei
    Lee, Dana
    James, Danelle F.
    Byrd, John C.
    O'Brien, Susan
    BLOOD, 2014, 124 (21)
  • [44] Randomized Trial of Ibrutinib Versus Ibrutinib Plus Rituximab (Ib plus R) in Patients with Chronic Lymphocytic Leukemia (CLL)
    Burger, Jan A.
    Sivina, Mariela
    Ferrajoli, Alessandra
    Jain, Nitin
    Kim, Ekaterina
    Kadia, Tapan
    Estrov, Zeev
    Gonzalez, Graciela Nogueras
    Huang, Xuelin
    Ohanian, Maro
    Andreeff, Michael
    Thomas, Mathew
    Alexander-Williams, Lynette
    Kantarjian, Hagop M.
    O'Brien, Susan M.
    Wierda, William G.
    Keating, Michael J.
    BLOOD, 2017, 130
  • [45] Ibrutinib for Chronic Lymphocytic Leukemia (CLL): A Single Center Experience in Bogota, Colombia
    Bohorquez, Leonardo
    Abello, Virginia
    Helena Solano, Maria
    Casas, Claudia
    Espinosa, Daniel
    Leon, Guillermo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S285 - S285
  • [46] Ibrutinib in patients with autoimmune cytopenias and previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) from the phase 3 RESONATETM study
    Montillo, Marco
    O'Brien, Susan
    Tedeschi, Alessandra
    Byrd, John
    Dearden, Claire
    Gill, Devinder
    Brown, Jennifer
    Barrientos, Jacqueline
    Mulligan, Stephen
    Furman, Richard
    Cymbalista, Florence
    Plascencia, Clara
    Chang, Stephen
    Hsu, Emily
    James, Danelle
    Hillmen, Peter
    LEUKEMIA & LYMPHOMA, 2015, 56 : 150 - 151
  • [47] Ibrutinib vs chlorambucil: Immunophenotypic and quantitative impacts on circulating immune cells in chronic lymphocytic leukemia (CLL).
    Solman, Isabelle
    You, Hana
    Taylor, Marlene
    Dubovsky, Jason A.
    Kipps, Thomas J.
    Burger, Jan Andreas
    Lal, Indu
    Chang, Betty Y.
    James, Danelle Frances
    Hill, John Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [48] Ibrutinib for Chronic Lymphocytic Leukemia
    Rigolin, Gian Matteo
    Cavazzini, Francesco
    Cuneo, Antonio
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (16): : 1593 - 1593
  • [49] CEREBRAL ASPERGILLOSIS IN A PATIENT WITH CHRONIC LYMPHATIC LEUKEMIA (CLL) TREATED WITH IBRUTINIB
    Ceballos, Bolanos C.
    Mugica, Munagorri, I
    Quispe, Cuba, I
    Alburquerque, Prieto C.
    Sanchez, Anton M. P.
    Sanchez, Iglesias J. M.
    Casamayor, Garcia A.
    Breeze, R. J.
    Mateos, Rodriguez M. C.
    Laxe, Vidal T.
    Cerezo, Aguirre C.
    Ibero, Esparza C.
    Redondo, Izal A. M.
    HAEMATOLOGICA, 2020, 105 : 230 - 231
  • [50] Cost of Illness of Japanese Patients with Chronic Lymphocytic Leukemia (CLL), and Budget Impact of the Market Introduction of Ibrutinib
    Mahlich J.
    Okamoto S.
    Tsubota A.
    PharmacoEconomics - Open, 2017, 1 (3) : 195 - 202
12345